EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

NUDT15 and TPMT Pharmacogenomic Testing for Azathioprine‐Induced Adverse Reactions in Immune‐Mediated Skin Diseases

Koramon Phuwaraks, Wimolsiri Iamsumang, Kunlawat Thadanipon, Chonlaphat Sukasem, Thawinee Jantararoungtong, Siwaporn Raksa, Vasanop Vachiramon, Nawara Sakpuwadol, Napapat Pongbangpho, Kumutnart Chanprapaph

Dermatologic Therapy · 2026-01 · 2026 (1)

DOI: 10.1155/dth/1890124 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Dermatologic Therapy, online erschienen am 22.06.2026. Verfasst von Koramon Phuwaraks und 9 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Mahidol University.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

While thiopurine S‐methyltransferase (TPMT) variants are known to correlate with azathioprine (AZA)‐induced adverse effects (AEs), nucleoside diphosphate‐linked moiety X Motif 15 (NUDT15) variants were reported to be more prevalent and correlated with AZA toxicity in Asians. However, the information of association between these genetic variants in immune‐mediated skin diseases (IMSDs) is limited.

Objective

To evaluate the prevalence of NUDT15 and TMPT genetic variants and their association with AZA‐induced AEs in patients with IMSDs. Materials and Methods Patients with IMSDs (e.g., autoimmune bullous diseases and vitiligo) who received AZA for ≥ 4 weeks were included. Data on clinical features, laboratory findings including NUDT15 and TPMT testing, AZA treatment regimens, and AZA‐associated AEs were reviewed and analyzed.

Results

Among 103 patients, 18 developed AEs: 13 with myelotoxicity alone, 4 with hepatotoxicity alone, and one with both. The prevalence of NUDT15 and TPMT variants was 16.5% and 2.9%, respectively. In multivariate analysis, both NUDT15 and TPMT variants were significantly associated with AZA‐induced myelotoxicity (OR = 13.56, 95%CI = 2.43–75.64, and p = 0.003 and OR = 42.65, 95%CI = 1.40–1300.13, and p = 0.031, respectively). However, none were significantly related to hepatotoxicity. For AZA‐induced myelotoxicity screening, isolated NUDT15 and TPMT tests are low in sensitivity (LR+ = 4.45, 95%CI = 2.03–9.75, sensitivity 50.0%, and specificity 88.8% and LR+ = 12.70, 95%CI = 1.23–131.00, sensitivity 14.3%, and specificity 98.9%, respectively). While the combination of both tests increases screening ability (LR+ = 5.72, 95%CI = 2.83–11.50, sensitivity 64.3%, and specificity 88.8%).

Conclusion

NUDT15 is more common than TPMT variants in Thais. In addition to TPMT, NUDT15 testing should be performed before the initiation of AZA to prevent AZA‐induced myelotoxicity in patients with IMSDs.

Förderung

  • Mahidol University

Zitieren

APA

Phuwaraks, K., Iamsumang, W., Thadanipon, K., Sukasem, C., Jantararoungtong, T., Raksa, S., Vachiramon, V., Sakpuwadol, N., Pongbangpho, N., & Chanprapaph, K. (2026). NUDT15 and TPMT Pharmacogenomic Testing for Azathioprine‐Induced Adverse Reactions in Immune‐Mediated Skin Diseases. Dermatologic Therapy, 2026(1). https://doi.org/10.1155/dth/1890124

Vancouver

Phuwaraks K, Iamsumang W, Thadanipon K, Sukasem C, Jantararoungtong T, Raksa S, et al. NUDT15 and TPMT Pharmacogenomic Testing for Azathioprine‐Induced Adverse Reactions in Immune‐Mediated Skin Diseases. Dermatologic Therapy. 2026;2026(1). doi:10.1155/dth/1890124

BibTeX
@article{Phuwaraks2026,
  author = {Phuwaraks, Koramon and Iamsumang, Wimolsiri and Thadanipon, Kunlawat and Sukasem, Chonlaphat and Jantararoungtong, Thawinee and Raksa, Siwaporn and Vachiramon, Vasanop and Sakpuwadol, Nawara and Pongbangpho, Napapat and Chanprapaph, Kumutnart},
  title = {NUDT15 and TPMT Pharmacogenomic Testing for Azathioprine‐Induced Adverse Reactions in Immune‐Mediated Skin Diseases},
  journal = {Dermatologic Therapy},
  year = {2026},
  volume = {2026},
  number = {1},
  doi = {10.1155/dth/1890124}
}
Kostenlos starten →